Insilico Medicine appoints Feng Ren as Chief Scientific Officer and Co-CEO
HIGHLIGHTS
- •Insilico Medicine appointment of Feng Ren as Chief Scientific Officer and Co-CEO
- •Feng Ren brings over 11 years of experience from GlaxoSmithKline and Medicilon, with a strong background in drug discovery and development
- •This appointment signifies Insilico Medicine's strategic expansion in drug discovery and development, leveraging Ren's extensive experience in the field
Published:
Official Source (Official Website)